338 related articles for article (PubMed ID: 28442242)
1. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.
Barry A; McPartlin A; Lindsay P; Wang L; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Pract Radiat Oncol; 2017; 7(5):e331-e337. PubMed ID: 28442242
[TBL] [Abstract][Full Text] [Related]
2. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Velec M; Haddad CR; Craig T; Wang L; Lindsay P; Brierley J; Brade A; Ringash J; Wong R; Kim J; Dawson LA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):939-946. PubMed ID: 28333016
[TBL] [Abstract][Full Text] [Related]
4. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Mantovani C; Fiandra C; Anglesio S; Ragona R
Acta Oncol; 2009; 48(4):571-7. PubMed ID: 19031164
[TBL] [Abstract][Full Text] [Related]
6. Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose?
Tanguturi SK; Niemierko A; Wo JY; Nguyen KN; Prichard H; Zhu AX; Wolfgang JA; Hong TS
Pract Radiat Oncol; 2017; 7(5):e323-e329. PubMed ID: 28341320
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.
Jun BG; Kim YD; Cheon GJ; Kim ES; Jwa E; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Lee SH; Kim HS
Korean J Intern Med; 2018 Nov; 33(6):1093-1102. PubMed ID: 28844122
[TBL] [Abstract][Full Text] [Related]
8. A mouse radiation-induced liver disease model for stereotactic body radiation therapy validated in patients with hepatocellular carcinoma.
Wu ZF; Zhang JY; Shen XY; Zhou LY; Gao YB; Hu Y; Zeng ZC
Med Phys; 2016 Jul; 43(7):4349. PubMed ID: 27370150
[TBL] [Abstract][Full Text] [Related]
9. Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma.
Dreher C; Høyer KI; Fode MM; Habermehl D; Combs SE; Høyer M
Acta Oncol; 2016 Jul; 55(7):886-91. PubMed ID: 26878669
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases.
Mondlane G; Ureba A; Gubanski M; Lind PA; Siegbahn A
Radiat Oncol; 2018 Oct; 13(1):206. PubMed ID: 30348194
[TBL] [Abstract][Full Text] [Related]
11. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of individualized stereotactic body radiotherapy of liver metastases.
Lee MT; Kim JJ; Dinniwell R; Brierley J; Lockwood G; Wong R; Cummings B; Ringash J; Tse RV; Knox JJ; Dawson LA
J Clin Oncol; 2009 Apr; 27(10):1585-91. PubMed ID: 19255313
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases.
McPartlin A; Swaminath A; Wang R; Pintilie M; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):388-395. PubMed ID: 28871989
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
[TBL] [Abstract][Full Text] [Related]
15. Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions.
Bae SH; Kim MS; Jang WI; Cho CK; Yoo HJ; Kim KB; Han CJ; Park SC; Lee DH
J Korean Med Sci; 2015 Aug; 30(8):1055-61. PubMed ID: 26240482
[TBL] [Abstract][Full Text] [Related]
16. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer.
Joo JH; Park JH; Kim JC; Yu CS; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Park J; Kim JH
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):876-883. PubMed ID: 29063852
[TBL] [Abstract][Full Text] [Related]
17. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
[TBL] [Abstract][Full Text] [Related]
18. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
Eriguchi T; Takeda A; Sanuki N; Oku Y; Aoki Y; Shigematsu N; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1006-11. PubMed ID: 23102838
[TBL] [Abstract][Full Text] [Related]
19. Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation.
Jawad MS; Fahim DK; Gerszten PC; Flickinger JC; Sahgal A; Grills IS; Sheehan J; Kersh R; Shin J; Oh K; Mantel F; Guckenberger M;
J Neurosurg Spine; 2016 Jun; 24(6):928-36. PubMed ID: 26895526
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
